地西他滨联合IAG/DAG治疗急性髓系白血病的临床疗效  

Therapeutic effect of decitabine combined with reduced IAG/DAG on acute myeloid leukemia

作　　者：梁兴林[1] 曾庆曙[1] 杨明珍[1] 黄震琪[1] 李庆生[1] 葛健[1] 夏瑞祥[1] LIANG Xinglin;ZENG Qingshu;YANG Mingzhen(Department of Hematology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)

机构地区：[1]安徽医科大学第一附属医院血液内科,合肥230022

出　　处：《安徽医学》2020年第5期519-521,共3页Anhui Medical Journal

基　　金：安徽省高校自然科学研究项目(项目编号:KJ2017A834)。

摘　　要：目的探讨地西他滨(DAC)联合IAG/DAG治疗急性髓系白血病(AML)的临床疗效与安全性。方法选取2017年6月至2019年12月安徽医科大学第一附属医院血液科收治的23例初治或复发AML患者,采用DAC联合IAG/DAG诱导治疗,统计分析临床疗效及安全性。结果23例患者均予以DAC联合IAG/DAG诱导化疗,其中完全缓解13例,部分缓解2例,总有效率为65.22%。23例患者均出现Ⅲ~Ⅳ级的粒细胞和血小板减少,1例患者因严重脑出血死亡。结论DAC联合IAG/DAG治疗AML临床疗效较好,且不良反应可耐受,安全性高,值得临床推广应用。Objective To observe the clinical efficacy and safety of decitabine combined with IAG/DAG in the treatment of acute myeloid leukemia(AML).Methods Twenty-three patients with AML admitted from June 2017 to December 2019 were treated with decitabine combined with IAG/DAG.The clinical efficacy and safety were evaluated.Results All 23 patients received decitabine combined with IAG/DAG induction chemotherapy.Among them,13 patients achieved complete remission,2 patients achieved partial remission,and the overall response rate was 65.22%.All patients had grade III^IV neutropenia and thrombocytopenia,and one patient died of severe cerebral hemorrhage.Non-hematologic toxicity such as gastrointestinal reactions,liver function damage and infection were controllable.Conclu sions Decitabine combined with IAG/DAG for AML has good clinical efficacy,tolerable adverse reactions,and high safety,thus it is worth clinical promotion and application for poor physical performance patients.

关 键 词：地西他滨 伊达比星 柔红霉素 急性髓系白血病 

分 类 号：R733.71[医药卫生—肿瘤]